Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term

Zacks Premium promotes its proprietary stock-rating methodology, which combines the Zacks Rank with Style Scores (Value, Growth, Momentum, VGM) to identify outperforming stocks, noting that #1 (Strong Buy) ranked stocks with A/B Style Scores historically yield the best returns. Hologic (HOLX), a medical technology firm, is highlighted as a potential momentum play, currently holding a Zacks #3 (Hold) rank but boasting B-level Momentum and VGM Style Scores. This outlook is supported by two recent upward revisions to its fiscal 2025 earnings estimate, increasing the consensus to $4.23 per share, and a historical average earnings surprise of +1%.

Analysis

Hologic (HOLX) presents a nuanced investment profile, marked by a neutral Zacks #3 (Hold) rating that contrasts with favorable B-grades for its Momentum and overall VGM Style Scores. The positive momentum signal is not derived from recent price action, as the stock has been flat with 0% change over the past four weeks, but rather from improving analyst sentiment. Specifically, two analysts have issued upward revisions for fiscal 2025 earnings estimates within the last 60 days. This has resulted in a marginal increase in the Zacks Consensus Estimate, which has risen by $0.01 to $4.23 per share. This forward-looking optimism is supported by a consistent, albeit modest, history of exceeding expectations, demonstrated by an average earnings surprise of +1%. The key consideration is whether this subtle positive shift in earnings outlook will be sufficient to act as a catalyst for future share price appreciation.

Key Decisions for Investors

• Investors should weigh the positive momentum in earnings estimates against the stock's neutral 'Hold' rating and recent flat price performance before committing new capital.
• Monitor upcoming earnings reports closely to see if the company can deliver a more significant beat than its historical +1% average surprise, which would be needed to validate the bullish sentiment.
• Consider the current situation as a potential leading indicator, but wait for evidence that the upward earnings revisions are translating into tangible price momentum before viewing it as a confirmed buy signal.